Epithalon

Epithalon is a synthetic tetrapeptide developed by the St. Petersburg Institute of Bioregulation and Gerontology. It mimics Epithalamin — a natural pineal extract used in decades of Russian anti-ageing research. It is the only substance demonstrated to activate telomerase in somatic cells, extending telomere length, which has implications for both longevity and cancer biology.

Properties

Amino Acid Sequence

Ala-Glu-Asp-Gly

Origin: Synthetic tetrapeptide based on Epithalamin — a polypeptide extract from the bovine pineal gland

Activates telomerase (hTERT) in normal somatic cells, restoring telomere length and delaying cell senescence. Regulates melatonin secretion from the pineal gland. Modulates cortisol and gonadotrophin levels. In tumour cells it paradoxically shows pro-apoptotic activity — possibly because cancer cells with already-active telomerase respond differently. Also downregulates oncogene expression and upregulates p53.

Russian clinical studies (V. Khavinson et al.) over 25 years show Epithalon reduces cancer incidence by 20–40% in elderly patient cohorts treated repeatedly. In animal models it reduces tumour metastasis, activates NK cells, and extends lifespan. Used in some integrative oncology protocols as an immune normaliser and cancer-prevention peptide rather than treatment. The telomerase-activation in normal cells is controversial given cancer's own use of telomerase — discuss with oncologist.

Links open on PubMed (National Library of Medicine). Research is ongoing — results may not reflect clinical use.

• Telomerase activation in normal cells is beneficial — but the context in active cancer is complex; discuss with oncologist
• Most human data from Russian studies (limited peer-reviewed publication in Western journals)
• Not approved by FDA or EMA; research compound only
• Should not be used as primary cancer treatment
• Refrigerate; reconstituted solution stable for 24–48 hours